Pneumocystis Pneumonia Occurring as a Complication during Infliximab Treatment for Psoriatic Arthritis

DOI Web Site
  • Iwata Yohei
    Department of Dermatology, Fujita Health University School of Medicine
  • Kobayashi Tsukane
    Department of Dermatology, Fujita Health University School of Medicine
  • Kanamori Satomi
    Division of Rheumatology and Infectious Diseases, Department of Internal Medicine, Fujita Health University School of Medicine
  • Nishino Jo
    Division of Rheumatology and Infectious Diseases, Department of Internal Medicine, Fujita Health University School of Medicine
  • Yagami Akiko
    Department of Dermatology, Fujita Health University School of Medicine
  • Matsunaga Kayoko
    Department of Dermatology, Fujita Health University School of Medicine

Bibliographic Information

Other Title
  • Infliximab治療中にニューモシスチス肺炎を発症した関節症性乾癬の1例
  • Infliximab チリョウ チュウ ニ ニューモシスチス ハイエン オ ハッショウ シタ カンセツショウセイカンセン ノ 1レイ

Search this article

Abstract

This study reports a psoriatic arthritis case that developed pneumocystis pneumonia (PCP) during infliximab treatment. A 61-year-old male had suffered from refractory arthralgia in his hands. Because non-steroidal anti-inflammatory drugs and methotrexate were not effective for controlling his disease, an administration of infliximab was initiated. After two courses of treatment, his articular symptoms dramatically improved. However, one month later, he developed PCP. There are no clear guidelines for evaluating PCP risk from biological drugs. It is necessary to carefully watch for any potential expression of PCP, despite its rarity. As infliximab therapy will be increasingly prescribed for many psoriasis patients in future, it will be necessary to identify which patients who are receiving infliximab therapy have a risk for PCP that is high enough to warrant prophylaxis.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top